Imitrex Articles
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
EUROPE STOCK COMMENT
10 January 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
GLAXO REAFFIRMS COMMITMENT TO R&D
6 December 1993
STRONG PERFORMANCE FROM GLAXO, AND ZANTAC
13 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
WILL THERE BE MORE FLEXIBILITY AT GLAXO UNDER SYKES?
28 June 1993
GLAXO'S SINGAPORE PLANT SET FOR 1994
15 February 1993
ANALYST TIPS GLAXO FOR CONTINUED SUCCESS
15 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
IMITREX SLOW TO GROW, SAY ANALYSTS
18 January 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
UK FIRMS BOOSTED BY YEAR-END US APPROVALS
4 January 1993
GLAXO'S IMITREX GETS FDA BACKING IN USA
14 December 1992
LONDON STOCK COMMENT
14 December 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
GLAXO PROSPECTS GLOOM: FACT OR FICTION?
3 August 1992
GLAXO INCREASES CNS EMPHASIS IN USA
13 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
